Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 6,236 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 6,236 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $27.86, for a total transaction of $173,734.96. Following the completion of the sale, the insider owned 304,270 shares in the company, valued at approximately $8,476,962.20. This trade represents a 2.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total value of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total value of $691,808.05.

Hims & Hers Health Trading Down 0.3%

NYSE:HIMS opened at $27.92 on Friday. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The business’s 50 day moving average is $30.19 and its two-hundred day moving average is $27.60. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $65.30. The company has a market cap of $6.51 billion, a PE ratio of -44.32 and a beta of 2.42.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.Hims & Hers Health’s revenue was up 38.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.17 EPS. On average, analysts predict that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on HIMS shares. Barclays lowered their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, August 21st. Citigroup dropped their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. TD Cowen upped their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Bank of America lifted their target price on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $32.43.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after buying an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in shares of Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares in the last quarter. Compass Financial Management LLC bought a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $50,000. Bogart Wealth LLC grew its stake in shares of Hims & Hers Health by 180.7% in the 1st quarter. Bogart Wealth LLC now owns 2,526 shares of the company’s stock worth $52,000 after purchasing an additional 1,626 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in Hims & Hers Health during the fourth quarter valued at approximately $59,000. 63.52% of the stock is owned by institutional investors.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: Bank of America Securities maintained its Hold rating on HIMS, signaling limited near-term conviction despite the stock’s decline. Bank of America Hold Rating
• Neutral Sentiment: COO Michael Chi sold 14,027 shares for approximately $398,000, while insider Soleil Boughton sold 6,236 shares for about $174,000. Both transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their significance as direct bearish signals, although they add to investor concern about insider selling. SEC Insider Filing
• Negative Sentiment: Several law firms announced or promoted a federal securities class action covering investors who bought HIMS shares between August 4, 2025, and July 29, 2026. Investors have until November 2, 2026 to seek lead-plaintiff status. Class Action Deadline Notice
• Negative Sentiment: The litigation stems from allegations related to the FTC’s complaint involving Hims & Hers’ privacy, data-sharing, billing and business practices. Plaintiffs allege the company made material misstatements or omissions about these issues. The claims remain allegations and have not been proven in court. HIMS Securities Lawsuit

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.